Inhibition of PLK1 by small interfering RNA or pharmacological inhibitors exerts antitumor effect in vitro and in vivo, providing strong preclinical and clinical support for the use of PLK1 inhibitors in cancer therapy (Degenhardt and Lampkin, 2010; Lens et al., 2010). Here, PLK1 is linked to cancer.